Evidence map›Paper›PMID 42668569›Full record

ArticleMolecular therapy. Oncology2026

Additive effect of Ruta graveolens bioactive phytoconstituents and cisplatin through PKC/MEK/ERK pathway in glioblastoma.

Grazia Romano, Valentina Morgera, Antonio Pezone, Samantha Messina, Paolo Rosa, Manuela Iovinella, Claudia Ciniglia, Maria Teresa Gentile, Antonio Porcellini, Antonia Feola

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Grazia RomanoDepartment of Biology, University of Naples "Federico II", Naples, Italy.
Valentina MorgeraDepartment of Biology, University of Naples "Federico II", Naples, Italy.
Antonio PezoneDepartment of Biology, University of Naples "Federico II", Naples, Italy.
Samantha MessinaDepartment of Science, Roma Tre University, Rome, Italy.
Paolo RosaDepartment of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Latina, Italy.
Manuela IovinellaDepartment of Environmental, Biological and Pharmaceutical Sciences and Technologies (DiSTABiF), University of Campania Luigi Vanvitelli, Caserta, Italy.
Claudia CinigliaDepartment of Environmental, Biological and Pharmaceutical Sciences and Technologies (DiSTABiF), University of Campania Luigi Vanvitelli, Caserta, Italy.
Maria Teresa GentileDepartment of Environmental, Biological and Pharmaceutical Sciences and Technologies (DiSTABiF), University of Campania Luigi Vanvitelli, Caserta, Italy.
Antonio PorcelliniDepartment of Biology, University of Naples "Federico II", Naples, Italy.
Antonia FeolaDepartment of Biology, University of Naples "Federico II", Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is a lethal malignancy with limited therapeutic options. Its aggressive progression and resistance to standard therapy necessitate the development of novel therapeutic strategies. Plant-based compounds have emerged as promising candidates for therapeutic development modulating key targets in cancer. The

Indexed as

bioactive compoundcell cycle arrestcisplatinCisplatin-de-escalationcombined therapyglioblastomaPKC/ERK/MEK signalingRuta graveolens

Identifiers

PMID42668569
PMCPMC13524684

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.